KDM5A and inclusion body myositis: As targeting both inflammatory and degenerative pathways in IBM with current treatments has proven to be unsuccessful, IBM research requires new therapeutic strategies based on novel and strong hypotheses and KDM5A might represent a relevant and druggable target [3, 4].